Kiromic BioPharma Accounts Payable

Kiromic BioPharma (KRBP) currently reports a accounts payable of $2.7M as of December 2024. That compares with $2.1M in the prior-year period — up 25.3% year over year. Use the charts on this page to explore Kiromic BioPharma's accounts payable history and peer comparisons.

Kiromic BioPharma's accounts payable increased from $2.1M to $2.7M — a 25.3% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kiromic BioPharma reported $2.7M in accounts payable as of December 2024. That compares with $2.1M in the prior-year period — up 25.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $2.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Kiromic BioPharma, and consider following KRBP for alerts when major investors trade the stock.

Kiromic BioPharma is classified in the Healthcare sector. On accounts payable, it currently shows $2.7M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KRBP with unrelated industries.